Please use this identifier to cite or link to this item:
Title: Lateral lumbar interbody fusion – outcomes, complications and fusion rates with recombinant human bone morphogenetic protein-2.
Epworth Authors: Malham, Gregory
Wang, Yi Yuen
Buckland, Aaron
Oehme, David
Other Authors: Morton, Matthew
Keywords: Direct Lateral Transpsoas Retroperitoneal Technique
Degenerative Disc Disease
Disc Herniation
Spinal Stenosis
Spinal Deformity
Lateral Lumbar Interbody Fusion
Minimally Invasive Large Interbody Cage
Visceral & Vascular injury
Neurosciences Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Oct-2022
Conference Name: Epworth HealthCare Research Month 2022
Conference Location: Epworth Research Institute, Victoria, Australia
Abstract: Direct lateral transpsoas retroperitoneal technique indicated for degenerative disc disease, disc herniation, spinal stenosis, deformity. Benefits: minimally invasive, large interbody cage for graft material, indirect neural decompression. Concerns: approach-related neuropraxia, visceral & vascular injury, safety at L4/5 rhBMP-2 boasts high fusion rates but is controversial around cost and potential adverse outcomes. Aims: 1.Report a consecutive series of patients undergoing LLIF with an emphasis on the clinical outcomes, fusion rates, and complication profile in particular neurological complications and complications occurring at L4/5 2.Report the use of rhBMP-2 in LLIF with an emphasis on the fusion rates and any adverse outcomes associated with its use.
Type: Conference Poster
Type of Clinical Study or Trial: Retrospective studies
Appears in Collections:Research Month

Files in This Item:
File Description SizeFormat  
Malham G Lateral Lumbar Interbody Fusion.pdf1.48 MBAdobe PDFThumbnail

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.